Juanjuan Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Juanjuan Xu has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Aiping Qin
Reproductive Medicine Research Center, The First Affiliated Hospital of Guangxi Medical University, Nanning, China
1 shared publication - Haiwei Li
Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi, China
1 shared publication - Jinmin Zhao
Department of Orthopaedics Trauma and Hand Surgery, The First Affiliated Hospital of Guangxi Medical University, China
1 shared publication - Li Xie
Department of Clinical Laboratory, The Second Affiliated Hospital of Guangxi Medical University
1 shared publication - Liwen Lin
Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi, China
1 shared publication - Qiliu Peng
Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
1 shared publication
Latest Publications
- Open Access
- 8 October 2012
- Published by Springer Nature in Diagnostic Pathology
- Vol. 7 (1) , 136
Association of COMT Val158Met polymorphism and breast cancer risk: an updated meta-analysis
Background: Catechol-O-methyltransferase (COMT) is one of the most important enzymes involved in estrogen metabolism and its functional genetic polymorphisms may be associated with breast cancer (BC) risk. Many epidemiological studies have been conducted to explore the association between theCOMTVal158Met polymorphism and breast cancer risk. However, the results remain inconclusive. In order to derive a more precise estimation of this relationship, a large meta-analysis was performed in this study.Methods: Systematic searches of the PubMed, Embase and Cochrane Library were performed. Crude odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to estimate the strength of the association.Results: A total of 56 studies including 34,358 breast cancer cases and 45,429 controls were included. Overall, no significant associations between theCOMTVal158Met polymorphism and breast cancer risk were found for LL versus HH, HL versus HH, LL versus HL, recessive model LL versus HL+HH, and dominant model LL+HL versus HH. In subgroup analysis by ethnicity, source of controls, and menopausal status, there was still no significant association detected in any of the genetic models.Conclusion: Our meta-analysis results suggest that theCOMTVal158Met polymorphism may not contribute to breast cancer susceptibility.Virtual slides: The virtual slides(s) for this article can be found here:http://www.diagnosticpathology.diagnomx.eu/vs4806123577708417
- 8 October 2012
- Published by Springer Nature in Diagnostic Pathology
- Vol. 7 (1) , 136
Open AccessAssociation of COMT Val158Met polymorphism and breast cancer risk: an updated meta-analysis
Background: Catechol-O-methyltransferase (COMT) is one of the most important enzymes involved in estrogen metabolism and its functional genetic polymorphisms may be associated with breast cancer (BC) risk. Many epidemiological studies have been conducted to explore the association between theCOMTVal158Met polymorphism and breast cancer risk. However, the results remain inconclusive. In order to derive a more precise estimation of this relationship, a large meta-analysis was performed in this study.Methods: Systematic searches of the PubMed, Embase and Cochrane Library were performed. Crude odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to estimate the strength of the association.Results: A total of 56 studies including 34,358 breast cancer cases and 45,429 controls were included. Overall, no significant associations between theCOMTVal158Met polymorphism and breast cancer risk were found for LL versus HH, HL versus HH, LL versus HL, recessive model LL versus HL+HH, and dominant model LL+HL versus HH. In subgroup analysis by ethnicity, source of controls, and menopausal status, there was still no significant association detected in any of the genetic models.Conclusion: Our meta-analysis results suggest that theCOMTVal158Met polymorphism may not contribute to breast cancer susceptibility.Virtual slides: The virtual slides(s) for this article can be found here:http://www.diagnosticpathology.diagnomx.eu/vs4806123577708417